Policy alternatives for treatments for rare diseases.
作者信息
Panju Abbas H, Bell Chaim M
机构信息
DeGroote School of Business, McMaster University, Hamilton, Ont.
出版信息
CMAJ. 2010 Nov 23;182(17):E787-92. doi: 10.1503/cmaj.081429. Epub 2010 Jul 12.
Abstract
摘要
相似文献
1
Policy alternatives for treatments for rare diseases.
CMAJ. 2010 Nov 23;182(17):E787-92. doi: 10.1503/cmaj.081429. Epub 2010 Jul 12.
2
Policymaking for Orphan Drugs and Its Challenges.
AMA J Ethics. 2015 Aug 1;17(8):776-9. doi: 10.1001/journalofethics.2015.17.8.pfor2-1508.
3
Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy.
CMAJ. 2006 Jan 17;174(2):189-90. doi: 10.1503/cmaj.050706.
4
The Orphan Drug Act Revisited.
JAMA. 2019 Mar 5;321(9):833-834. doi: 10.1001/jama.2019.0290.
5
Regulators adopt more orphan drugs.
Nature. 2014 Apr 3;508(7494):16-7. doi: 10.1038/508016a.
6
Rare diseases and effective treatments: are we delivering?
Lancet. 2015 Feb 28;385(9970):750-2. doi: 10.1016/S0140-6736(15)60297-5.
7
Adopting an orphan.
EMBO Rep. 2005 Jun;6(6):507-10. doi: 10.1038/sj.embor.7400450.
8
A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
J Public Health Policy. 2010 Dec;31(4):407-20; discussion 420-1. doi: 10.1057/jphp.2010.30.
9
HHS defends expanded 340B drug discounts.
Mod Healthc. 2014 Jun 16;44(24):9.
10
Confusion over Article 8.
EMBO Rep. 2005 Aug;6(8):690. doi: 10.1038/sj.embor.7400485.
引用本文的文献
1
A systematic review of moral reasons on orphan drug reimbursement.
Orphanet J Rare Dis. 2021 Jun 30;16(1):292. doi: 10.1186/s13023-021-01925-y.
2
Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations.
Pharmacoeconomics. 2019 Oct;37(10):1261-1276. doi: 10.1007/s40273-019-00816-2.
3
Scoping Review on Use of Drugs Targeting Interleukin 1 Pathway in DIRA and DITRA.
Dermatol Ther (Heidelb). 2018 Dec;8(4):539-556. doi: 10.1007/s13555-018-0269-7. Epub 2018 Nov 3.
4
Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis.
Pharmacoeconomics. 2018 Oct;36(10):1253-1261. doi: 10.1007/s40273-018-0669-7.
5
Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
Orphanet J Rare Dis. 2018 Jan 30;13(1):27. doi: 10.1186/s13023-018-0759-9.
6
Determinants of orphan drugs prices in France: a regression analysis.
Orphanet J Rare Dis. 2017 Apr 21;12(1):75. doi: 10.1186/s13023-016-0561-5.
7
Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Orphanet J Rare Dis. 2016 Jun 4;11(1):72. doi: 10.1186/s13023-016-0455-6.
8
Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.
Healthc Policy. 2016 May;11(4):70-81.
9
Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
Healthc Policy. 2015 Aug;11(1):15-32.
10
Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach.
Orphanet J Rare Dis. 2013 Nov 16;8:180. doi: 10.1186/1750-1172-8-180.
本文引用的文献
1
The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).
J Inherit Metab Dis. 2010 Aug;33(4):331-8. doi: 10.1007/s10545-010-9095-5. Epub 2010 Jun 2.
2
Enzyme therapy for Fabry patients in jeopardy.
CMAJ. 2009 Sep 15;181(6-7):E120. doi: 10.1503/cmaj.109-3013.
3
Orphan drug legislation: lessons for neglected tropical diseases.
Int J Health Plann Manage. 2009 Jan-Mar;24(1):27-42. doi: 10.1002/hpm.930.
4
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Arch Intern Med. 2007 May 28;167(10):1041-9. doi: 10.1001/archinte.167.10.1041.
5
Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease.
Curr Opin Gastroenterol. 2007 Mar;23(2):149-58. doi: 10.1097/MOG.0b013e32802086d0.
6
The French 'observatoire' on Gaucher's disease.
Eur J Intern Med. 2006 Nov;17 Suppl:S6-8. doi: 10.1016/j.ejim.2006.07.002.
7
Rare disease research gets boost.
JAMA. 2006 Jun 28;295(24):2836-8. doi: 10.1001/jama.295.24.2836.
8
Outpatient gatifloxacin therapy and dysglycemia in older adults.
N Engl J Med. 2006 Mar 30;354(13):1352-61. doi: 10.1056/NEJMoa055191. Epub 2006 Mar 1.
9
Orphan drug development is progressing too slowly.
Br J Clin Pharmacol. 2006 Mar;61(3):355-60. doi: 10.1111/j.1365-2125.2006.02579.x.
10
Adopting orphan drugs--two dozen years of treating rare diseases.
N Engl J Med. 2006 Feb 2;354(5):445-7. doi: 10.1056/NEJMp058317.
Zotero 插件